BioSpace News Archive

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, will host its Investor Day and Site Visit (“Genomma Day”) on Wednesday, March 8, 2023 in Mexico.

PENTAX Medical America has launched a new fast endoscope drying solution - the PlasmaTYPHOONdry.

Boston Children’s Health Physicians is pleased to announce the addition of four primary care offices to our network of care.

Terns Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 10,350,000 shares of its common stock at a public offering price of $7.25 per share, before underwriting discounts and commissions.

QureBio Ltd. today announced that Phase Ⅰ Clinical Data of its Q-1802 program will be presented at ASCO Gastrointestinal Cancers Symposium (ASCO-GI) hold at the San Francisco and online on January 19–21, 2023.

Abivax SA (Euronext Paris:FR0012333284 - ABVX) today announced that the US Food and Drug Administration (the FDA) provided their agreement on the initial Pediatric Study Plan (iPSP) for the development of obefazimod in ulcerative colitis in children from 2 to 17 years old.

Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the FDA’s approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.

CVRx, Inc. announced that Kevin Hykes will join its Board of Directors effective December 21, 2022.

Radius Health, Inc. (“Radius” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved TYMLOS® (abaloparatide), a parathyroid hormone related peptide [PTHrP(1‑34)] analog, as a treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or in patients who have failed or are intolerant to other available osteoporosis therapy.

Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) and Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) today jointly announced an option grant agreement through which Vaxcyte acquired an option to access expanded rights to develop and manufacture cell-free extract, among other rights.